Navigation Links
Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
Date:6/11/2008

GOTHENBURG, Sweden, June 11 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, today announced a new collaborative agreement with AstraZeneca. Under the agreement Cellectricon will provide AstraZeneca with two of its new groundbreaking high throughput platform, Dynaflow(R)HT, for ion channel screening.

Cellectricon and AstraZeneca formed and announced a collaboration in May 2006 aiming to find a solution to major bottlenecks in ligand gated ion channel screening. The results from this collaboration have successfully demonstrated the unique performance of Cellectricon's cell-based microfluidic screening platform. It has clearly demonstrated the opportunity to introduce the fully automated Dynaflow(R)HT System with unmatched level of stability and throughput while still delivering unique measurement data quality. The Dynaflow(R)HT System will be launched and commercially available in 2009.

"Collaborating with AstraZeneca has been most rewarding," says Jonas Ohlsson, CEO at Cellectricon. "Driven by solving bottlenecks in drug discovery, Cellectricon's strategy is to bring state-of-the-art products for drug discovery and research to the market through world-class customer collaborations."

"This collaboration aims to accelerate our efforts in ion channel drug discovery and has been very fruitful to date. We look forward to working with the Dynaflow@HT Systems and see the impact of their throughput and cost effectiveness," says Dr. Jan-Erik Nystrom, VP Local Discovery Research Area CNS & Pain Control, Sodertalje, Sweden.

"The strength of this platform is that it is based on many years of cutting-edge academic and industrial research in ion channel drug discovery. I am happy to see us taking a new step together with a leading partner in advancing it further," says Dr. Jon Sinclair, VP Research & Development at Cellectricon.

About Cellectricon

Cellectricon AB (http://www.cellectricon.com), a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007 the company increased its annual revenue by almost 50%. In 2008-2009 the company will launch two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.


'/>"/>
SOURCE Cellectricon AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
2. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
5. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
6. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
7. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
8. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
9. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
10. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
11. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series ... 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population ... challenge of how to continue to feed a growing nation. At the same time, ...
(Date:10/7/2017)... , ... October 06, 2017 ... ... experience providing advanced instruments and applications consulting for microscopy and surface analysis, ... in application consulting, Nanoscience Analytical offers a broad range of contract analysis ...
Breaking Biology Technology:
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
Breaking Biology News(10 mins):